Korro Bio (NASDAQ:KRRO) Trading 5.3% Higher

Korro Bio, Inc. (NASDAQ:KRROGet Free Report)’s stock price rose 5.3% during mid-day trading on Friday . The company traded as high as $53.96 and last traded at $53.96. Approximately 8,208 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 28,692 shares. The stock had previously closed at $51.26.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on KRRO shares. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price objective on shares of Korro Bio in a research note on Wednesday, March 27th. HC Wainwright cut their price target on shares of Korro Bio from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday. BMO Capital Markets reiterated an “outperform” rating and issued a $120.00 price target on shares of Korro Bio in a report on Wednesday. Finally, Royal Bank of Canada upped their price objective on Korro Bio from $70.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, March 27th.

Read Our Latest Report on Korro Bio

Korro Bio Stock Performance

The stock has a 50-day moving average of $65.99.

Insider Transactions at Korro Bio

In related news, major shareholder Venture Opportunity Fund Atlas purchased 17,857 shares of the stock in a transaction that occurred on Monday, April 22nd. The stock was purchased at an average cost of $56.00 per share, for a total transaction of $999,992.00. Following the acquisition, the insider now owns 195,074 shares in the company, valued at $10,924,144. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 16.80% of the company’s stock.

Institutional Trading of Korro Bio

Several large investors have recently bought and sold shares of KRRO. North Star Investment Management Corp. purchased a new position in Korro Bio in the 4th quarter valued at about $48,000. Atlas Venture Life Science Advisors LLC purchased a new position in Korro Bio in the fourth quarter valued at about $53,648,000. Monashee Investment Management LLC purchased a new stake in Korro Bio during the 4th quarter worth approximately $4,352,000. 72 Investment Holdings LLC purchased a new position in shares of Korro Bio during the 4th quarter valued at approximately $13,269,000. Finally, Eventide Asset Management LLC acquired a new stake in shares of Korro Bio during the fourth quarter worth approximately $26,185,000. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Company Profile

(Get Free Report)

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Featured Articles

Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.